Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus envelope glycoproteins (EBV envelope glycoproteins)
- Target
- EBV envelope glycoproteins
- Molecular classification
- Viral envelope glycoprotein, Class III fusion protein (gB), Receptor-binding protein (gp350/220, gp42), Membrane fusion machinery (gB, gH/gL, gp42)
01
Overview
Epstein-Barr virus envelope glycoproteins are functional proteins embedded in the viral envelope that mediate attachment, receptor binding, and fusion with the host cell membrane, thereby enabling viral entry. The most prominent glycoproteins include gp350/220, which binds the B cell receptor CR2/CD21, and the fusion machinery composed of gB (the principal fusion protein), gH/gL (forming a heterodimeric regulatory complex), and gp42 (modulates tropism between B cells and epithelial cells). These glycoproteins serve as targets for vaccine and therapeutic antibody development, since blocking their interactions can prevent virus entry and infection[1][2][3][4][5][6].
- Other names
- EBV glycoprotein B (gB)EBV glycoprotein H (gH)EBV glycoprotein L (gL)EBV glycoprotein 350/220 (gp350/220)EBV glycoprotein 42 (gp42)Epstein-Barr virus glycoproteins
02
Mechanism of action
Inhibition of glycoprotein–receptor interaction (e.g., blocking gp350–CR2 binding) Blockade of membrane fusion (e.g., react with gB/gH/gL/gp42 complex to prevent conformational rearrangements) Neutralization of virus by antibody binding to glycoproteins
03
Biological functions
Virus entryMembrane fusionHost cell receptor bindingDetermining cell tropismInitiation of infection
04
Disease associations
InfectionCancer (e.g., lymphoma, nasopharyngeal carcinoma; EBV entry into cells is required for oncogenic transformation)Other (EBV is associated with a spectrum of lymphoproliferative and epithelial pathologies)
05
Safety considerations
Off-target immune responses (risk with vaccines and monoclonal antibodies)Antigenic variability (potential for viral escape, especially for vaccines and monoclonals)Possible adverse events with immune-modulatory therapies against EBV envelope glycoproteins (theoretical, not extensively documented)
06
Interacting drugs
Monoclonal antibodies targeting gp350 (experimental and in development)
3 more in the full profile.
07
Biomarkers
gp350 levels (may distinguish active EBV replication)Antibody response against EBV glycoproteins (used for serological diagnosis of infection and sometimes for monitoring vaccine efficacy)
Beyond the preview
Go deeper on Epstein-Barr virus envelope glycoproteins (EBV envelope glycoproteins).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epstein-Barr virus envelope glycoproteins (EBV envelope glycoproteins).